osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['osimertinib', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
chrysalis-2: #amivantamab plus #lazertinib in egfr-mutant nsclc after progression on #osimertinib and platinum chemotherapy by n=162
orr=33%
mpfs=5.1 months
mos=14.8 months evidence of cns activity seen active regimen post-osimertinib/chemo setting! #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM